Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

被引：7

作者：

Atesoglu, Elif Birtas ^{[1
]}

Gulbas, Zafer ^{[2
]}

Uzay, Ant ^{[3
]}

Ozcan, Muhit ^{[4
]}

Ozkalemkas, Fahir ^{[5
]}

Dal, Mehmet Sinan ^{[6
]}

Kalyon, Hakan ^{[1
]}

Akay, Olga Meltem ^{[1
]}

Deveci, Burak ^{[7
]}

Bekoz, Huseyin ^{[8
]}

Sevindik, Omur Gokmen ^{[8
]}

Toptas, Tayfur ^{[9
]}

Yilmaz, Fergun ^{[9
]}

Koyun, Derya ^{[4
]}

Alkis, Nihan ^{[10
]}

Alacacioglu, Inci ^{[11
]}

Sonmez, Mehmet ^{[12
]}

Yavasoglu, Irfan ^{[13
]}

Tombak, Anil ^{[14
]}

Mehtap, Ozgur ^{[15
]}

Kurnaz, Fatih ^{[16
]}

Yuce, Orhan Kemal ^{[17
]}

Karakus, Volkan ^{[18
]}

Turgut, Mehmet ^{[19
]}

Kurekci, Derya Deniz ^{[19
]}

Ayer, Mesut ^{[20
]}

Keklik, Muzaffer ^{[21
]}

Buyuktas, Deram ^{[22
]}

Ozbalak, Murat ^{[20
]}

Ferhanoglu, Burhan ^{[1
,23
,24
]}

机构：

[1] Koc Univ, Dept Internal Med, Div Hematol, Sch Med, Istanbul, Turkiye

[2] Anadolu Med Ctr, Div Hematol, Kocaeli, Turkiye

[3] Acibadem Atakent Hosp, Div Hematol, Istanbul, Turkiye

[4] Ankara Univ, Dept Internal Med, Div Hematol, Med Fac, Ankara, Turkiye

[5] Uludag Univ, Dept Internal Med, Div Hematol, Med Fac, Bursa, Turkiye

[6] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Div Hematol, Ankara, Turkiye

[7] Medstar Hosp, Div Hematol, Antalya, Turkiye

[8] Medipol Univ, Dept Internal Med, Div Hematol, Med Fac, Istanbul, Turkiye

[9] Marmara Univ, Dept Internal Med, Div Hematol, Med Fac, Istanbul, Turkiye

[10] Bursa City Hosp, Div Hematol, Bursa, Turkiye

[11] Dokuz Eylul Univ, Dept Internal Med, Div Hematol, Med Fac, Izmir, Turkiye

[12] Karadeniz Tech Univ, Dept Internal Med, Div Hematol, Med Fac, Trabzon, Turkiye

[13] Adnan Menderes Univ, Dept Internal Med, Div Hematol, Med Fac, Aydin, Turkiye

[14] Mersin Univ, Dept Internal Med, Div Hematol, Med Fac, Mersin, Turkiye

[15] Kocaeli Univ, Dept Internal Med, Div Hematol, Med Fac, Kocaeli, Turkiye

[16] Kocaeli Medicalpark Hosp, Div Hematol, Kocaeli, Turkiye

[17] Akdeniz Univ, Dept Internal Med, Div Hematol, Med Fac, Antalya, Turkiye

[18] Antalya Res & Training Hosp, Div Hematol, Antalya, Turkiye

[19] Ondokuzmayis Univ, Dept Internal Med, Div Hematol, Med Fac, Samsun, Turkiye

[20] Basaksehir Cam ve Sakura City Hosp, Div Hematol, Istanbul, Turkiye

[21] Erciyes Univ, Dept Internal Med, Div Hematol, Med Fac, Kayseri, Turkiye

[22] VKV Amer Hosp, Div Hematol, Istanbul, Turkiye

[23] Koc Univ, Sch Med, Dept Hematol, Istanbul, Turkiye

[24] VKV Amer Hosp, Dept Hematol, Istanbul, Turkiye

来源：

HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷 / 04期

关键词：

bispecific antibodies; glofitamab; relapsed; refractory diffuse large B-cell lymphoma; SINGLE-ARM; OPEN-LABEL; MULTICENTER;

D O I：

10.1002/hon.3174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patients with relapsed/refractory (R/R) B-cell lymphoma. However, the real-world data of patients of all ages with no strict selection criteria are still lacking. Herein, this retrospective study aimed to evaluate the outcomes of diffuse large B-cell lymphoma (DLBCL) patients who received glofitamab via compassionate use in Turkey. Forty-three patients from 20 centers who received at least one dose of the treatment were included in this study. The median age was 54 years. The median number of previous therapies was 4, and 23 patients were refractory to first-line treatment. Twenty patients had previously undergone autologous stem cell transplantation. The median follow-up time was 5.7 months. In efficacy-evaluable patients, 21% and 16% of them achieved complete response and partial response, respectively. The median response duration was 6.3 months. The median progression-free survival (PFS) and overall survival (OS) was 3.3 and 8.8 months, respectively. None of the treatment-responsive patients progressed during the study period, and their estimated 1-year PFS and OS rate was 83%. The most frequently reported toxicity was hematological toxicity. Sixteen patients survived, while 27 died at the time of the analysis. The most common cause of death was disease progression. One patient died of cytokine release syndrome during the first cycle after receiving the first dose of glofitamab. Meanwhile, two patients died due to glofitamab-related febrile neutropenia. This is the largest real-world study on the effectiveness and toxicity of glofitamab treatment in R/R DLBCL patients. The median OS of 9 months seems promising in this heavily pretreated group. The toxicity related mortality rates were the primary concerns in this study.

引用

页码：663 / 673

页数：11

共 50 条

[1] Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data
Ferhanoglu, Burhan
Gulbas, Zafer
Uzay, Ant
Ozcan, Muhit
Ozkalemkas, Fahir
Dal, Mehmet Sinan
Kalyon, Hakan
Akay, Olga Meltem
Deveci, Burak
Bekoz, Huseyin
Sevindik, Omur Gokmen
Toptas, Tayfur
Yilmaz, Asu Fergun
Koyun, Derya
Alkis, Nihan
Atesoglu, Elif Birtas
[J]. BLOOD, 2022, 140 : 6704 - 6705
[2] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, Michael J.
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Trney, Marek
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
[3] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
Crombie, Jennifer L.
Jun, Monika
Wang, Tongsheng
Mutebi, Alex
Wang, Anthony
Chhibber, Anindit
Kamalakar, Rajesh
Ukropec, Jon
Blaedel, Julie
Kalsekar, Anupama
[J]. LEUKEMIA & LYMPHOMA, 2024,
[4] Glofitamab in Relapsed Refractory Diffuse Large B-Cell Lymphoma: Single Center Experience
Yaman, Samet
Candir, Burcu Aslan
Bozan, Ersin
Dal, Mehmet Sinan
Altuntas, Fevzi
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S445 - S445
[5] The Use of Glofitamab in Relapsed Diffuse Large B-Cell Lymphoma
Falchi, Lorenzo
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01) : 12 - 15
[6] Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Andrew Ip
Alex Mutebi
Tongsheng Wang
Monika Jun
Anupama Kalsekar
Fernando Rivas Navarro
Anthony Wang
Rajesh Kamalakar
Mariana Sacchi
Brian Elliott
[J]. Advances in Therapy, 2024, 41 : 1226 - 1244
[7] Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Ip, Andrew
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Kalsekar, Anupama
Navarro, Fernando Rivas
Wang, Anthony
Kamalakar, Rajesh
Sacchi, Mariana
Elliott, Brian
[J]. ADVANCES IN THERAPY, 2024, 41 (03) : 1226 - 1244
[8] Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
Chien, Hsu-Chih
Morreall, Deborah
Patil, Vikas
Rasmussen, Kelli M.
Li, Chungyang
Yong, Christina M.
Burningham, Zachary
Masaquel, Anthony
Halloran, Mary
De Long-Sieg, Elisha
Schulz, Mathias
Sauer, Brian C.
Halwani, Ahmad S.
[J]. FUTURE ONCOLOGY, 2020, 17 (04) : 411 - 422
[9] REAL-WORLD TREATMENT PATTERNS AND COSTS IN RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
Mutebi, A.
Jun, M.
Flores, C.
Wang, Z.
Wang, A.
Elliot, B.
Navarro, F. R.
Kalsekar, A.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S394 - S394
[10] Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma
Gatwood, Justin
Masaquel, Anthony
Fox, David
Sheinson, Daniel
James, Cameron
Li, Jia
Hossain, Farah
Ross, Ryan
[J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 738 - 745

← 1 2 3 4 5 →